Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults
Extract
We thank Y. Li and co-workers for their interest in the European Respiratory Society/European Society of Thoracic Surgeons statement on the management of pleural infection, recently published in the European Respiratory Journal [1]. Our interpretation of their correspondence is that they have misunderstood "IPC" to denote a standard chest drain or tube used, with a well-established evidence base, in the acute management of pleural infection [2]. This is also sometimes referred to as an intercostal catheter or an intercostal drain. In the statement, IPC refers specifically to "indwelling pleural catheter", and the a...
Source: European Respiratory Journal - March 14, 2024 Category: Respiratory Medicine Authors: Bedawi, E. O., Rahman, N. M. Tags: Correspondence Source Type: research
Insights on the ERS/ESTS statement on the management of pleural infection in adults
Extract
We read with great interest the article by Bedawi et al. [1], recently published in the prestigious European Respiratory Journal, on the management of pleural infection in adults. We highly commend this work and here we wish to focus on the management of pleural infection with indwelling pleural catheters (IPC). The statement suggested that recurrent or chronic pleural infection created difficult management issues, especially in those with trapped lung and where there was no surgical option [1]. However, we reviewed previous publications and wish to bring forth some different insights on the management of pleural i...
Source: European Respiratory Journal - March 14, 2024 Category: Respiratory Medicine Authors: Li, Y., Zeng, H., Tian, P., Li, W. Tags: Correspondence Source Type: research
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target
(Source: European Respiratory Journal)
Source: European Respiratory Journal - March 14, 2024 Category: Respiratory Medicine Authors: Gerges, C., Montani, D., Humbert, M., Lang, I. M. Tags: RESEARCH LETTER Source Type: research
Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study "PC-COS Children"
The coronavirus disease 2019 (COVID-19) pandemic substantially impacted different age groups, with children and young people not exempted. Many have experienced enduring health consequences. Presently, there is no consensus on the health outcomes to assess in children and young people with post-COVID-19 condition. Furthermore, it is unclear which measurement instruments are appropriate for use in research and clinical management of children and young people with post-COVID-19. To address these unmet needs, we conducted a consensus study, aiming to develop a core outcome set (COS) and an associated core outcome measurement ...
Source: European Respiratory Journal - March 14, 2024 Category: Respiratory Medicine Authors: Seylanova, N., Chernyavskaya, A., Degtyareva, N., Mursalova, A., Ajam, A., Xiao, L., Aktulaeva, K., Roshchin, P., Bobkova, P., Aiyegbusi, O. L., Anbu, A. T., Apfelbacher, C., Asadi-Pooya, A. A., Ashkenazi-Hoffnung, L., Brackel, C., Buonsenso, D., de Groot Tags: Respiratory infections and tuberculosis Original Articles: Long COVID series Source Type: research
Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry
Extract
Pulmonary embolism (PE) is a condition in which thrombus, usually embolised from the veins of the pelvis or lower limbs, obstructs the pulmonary arterial vascular bed. The incidence of PE is estimated at 60–70 per 100 000 per year [1] with a 1-year mortality of 15% [2, 3]. In survivors, patency of the pulmonary vasculature is restored, in most patients, within the first few months [4]. However, pulmonary emboli may not resolve and patients may also develop a chronic obstructing microvasculopathy [5, 6]. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 14, 2024 Category: Respiratory Medicine Authors: Durrington, C., Hurdman, J. A., Elliot, C. A., Maclean, R., Van Veen, J., Saccullo, G., De-Foneska, D., Swift, A. J., Smitha, R., Hill, C., Thomas, S., Dwivedi, K., Alabed, S., Wild, J. M., Charalampopoulos, A., Hameed, A., Rothman, A. M. K., Watson, L., Tags: Pulmonary vascular disease Original Articles: Pulmonary vascular disease Source Type: research
Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap
Extract
Cystic fibrosis (CF) is one of the most common autosomal recessive genetic conditions that causes progressive lung disease and premature death [1]. Median survival worldwide is estimated to be around 50 years, but there is variation between countries [2–4]. Reasons for this variation are complex, and include genetic factors such as cystic fibrosis transmembrane conductance regulator (CFTR) genetic mutations in the population [5], as well as non-genetic factors such as access to lung transplantation and socioeconomic status (SES) [4]. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: McKone, E. F. Tags: Editorials Source Type: research
Some future directions for genome-wide association studies of preserved ratio impaired spirometry
Extract
We read with interest the paper by Higbee et al. [1] that was recently published in the European Respiratory Journal. They discovered 22 single nucleotide polymorphisms (SNPs) associated with preserved ratio impaired spirometry (PRISm) through a two-stage sample population, four of which were associated with lung function, highlighting the usefulness of performing genome-wide association study (GWAS) of different lung function traits and phenotypes to maximise discovery of heritable genetic variants of lung function and disease, and that genetic risk factors for PRISm overlap with those for other lung diseases and ...
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Jin, Z., Wang, G. Tags: Correspondence Source Type: research
Omics-based profiles and biomarkers of respiratory infections: are we there yet?
Extract
From the influenza pandemic of 1918–1919 to the most recent COVID-19 pandemic, respiratory infections remain a leading cause of mortality worldwide [1, 2]. Concurrently, the development of high-throughput omics technologies has revolutionised research about host responses to known and emerging respiratory pathogens [3], accelerating our understanding of highly prevalent pulmonary diseases [4]. Notably, omics technology-based characterisation of pathogens and host pathophysiology have critically supported diagnostic and therapeutic global health efforts during both the influenza A H1N1 and SARS-CoV-2 pandemics...
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Pantaleon Garcia, J., Evans, S. E. Tags: Editorials Source Type: research
High altitude travelling with pulmonary arterial hypertension
Extract
Altitude exposure is generally considered to be contraindicated in pulmonary arterial hypertension (PAH), out of concern that (hypobaric) hypoxic pulmonary vasoconstriction (HPV) might further increase pulmonary vascular resistance (PVR) and worsen right heart failure [1]. This notion is mentioned in the guidelines of the European Society of Cardiology (ESC) and European Respiratory Society (ERS), who provide a recommendation against the travel to altitude of >1500 m without supplemental oxygen [2, 3]. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Naeije, R. Tags: Editorials Source Type: research
Endotypic traits of supine position and supine-predominant obstructive sleep apnoea in Asian patients
Conclusions
Supine-predominant OSA is the prevalent phenotype of OSA in Asian patients. Inadequate upper airway compensation appears to be a crucial underlying pathology in patients with supine-predominant OSA. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Cheng, W.-J., Finnsson, E., Agustsson, J. S., Sands, S. A., Hang, L.-W. Tags: Sleep medicine Original Articles: Sleep and ventilation Source Type: research
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis
Extract
The enzyme leukotriene A4 hydrolase (LTA4H) is classically known for its epoxide hydrolase activity that converts leukotriene A4 (LTA4) to the neutrophil chemoattractant LTB4 [1]. In 2010, our group published a study in Science that demonstrated that during an influenza model of acute airway inflammation, LTA4H was released from cells to degrade proline-glycine-proline (PGP), a non-canonical CXCR1 and -2 agonist of polymorphonuclear neutrophil (PMN) recruitment and activation [2], thereby attenuating PMN inflammation [3]. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Xu, X., Li, J.-d., Green, T. J., Wilson, L., Genschmer, K., Russell, D., Blalock, J. E., Gaggar, A. Tags: Research Letters Source Type: research
Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain
Conclusion
This pan-European analysis demonstrates a consistent improvement in FEV1 % pred, number of adult pwCF and survival over the last decade only in European higher and middle income countries. Urgent action is needed in the lower income countries where such improvement was not observed. The notable improvement observed in pwCF carrying the F508del mutation emphasises the need to develop treatments for all CF mutations. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Kerem, E., Orenti, A., Adamoli, A., Hatziagorou, E., Naehrlich, L., Sermet-Gaudelus, I., and the ECFS Patient Registry Steering Group Tags: CF and non-CF bronchiectasis Original Articles: Cystic fibrosis Source Type: research
The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled crossover trial
Conclusions
Among predominantly low-risk patients with stable PAH/CTEPH, cycling exercise during the first day at 2500 m was well tolerated, but peak exercise capacity, blood oxygenation and ventilatory efficiency were lower compared with 470 m. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Müller, J., Titz, A., Schneider, S. R., Bauer, M., Mayer, L., Lüönd, L., Ulrich, T., Furian, M., Forrer, A., Schwarz, E. I., Bloch, K. E., Lichtblau, M., Ulrich, S. Tags: Pulmonary vascular disease Original Articles: Pulmonary vascular disease Source Type: research
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection
Conclusions
SARS-CoV-2 infection results in the sustained presence of circulating neutrophils with distinct proteomes suggesting altered metabolic and immunosuppressive profiles and altered capacities to respond to migratory signals and cues from other immune cells, pathogens or cytokines. (Source: European Respiratory Journal)
Source: European Respiratory Journal - March 7, 2024 Category: Respiratory Medicine Authors: Long, M. B., Howden, A. J. M., Keir, H. R., Rollings, C. M., Giam, Y. H., Pembridge, T., Delgado, L., Abo-Leyah, H., Lloyd, A. F., Sollberger, G., Hull, R., Gilmour, A., Hughes, C., New, B. J. M., Cassidy, D., Shoemark, A., Richardson, H., Lamond, A. I., Tags: Respiratory infections and tuberculosis Original Articles: COVID-19 Source Type: research
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
Extract
In their correspondence, M. Dooney and T. Saba propose further analysis of the recently published data originating from the French compassionate programme for elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) and no F508del variant [1]. They suggest that ETI eligibility criteria should be based on the absence of "known to be unresponsive" variants rather than on the presence of variants with a "known response". Adapting data from the Vertex Pharmaceuticals phase 3 trial on F508del/minimal function variants, they provide a list of variants that are "known to be highly likely" not to respond ...
Source: European Respiratory Journal - February 29, 2024 Category: Respiratory Medicine Authors: Burgel, P.-R. Tags: Correspondence Source Type: research
